A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
← catalyst calendarNCT07700238 · readout in 1,122 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
126estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-20 | estimated | When the study began enrolling |
| Primary completion | 2029-09-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Immune Thrombocytopenia
Interventions
- Drug: Romiplostim — also filed as AMG 531, Nplate®
- Drug: Predniso(lo)ne
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants With a Durable Platelet Response (DPR)
measured 8 weeks
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed